Introduction
============

Polycystic ovary syndrome (PCOS) is the commonest endocrine disorder in women of reproductive age (prevalence 8--13%) ([@bib1]). Chronic anovulation, hyperandrogenism and ovarian polycystic morphology are the defining features of PCOS.

PCOS is associated with multiple comorbidities including obesity, insulin resistance (IR), dyslipidaemia, gestational diabetes (GDM), type 2 diabetes (T2D), hypertension, non-alcoholic fatty liver disease, impaired quality of life (QOL), cardiovascular disease (CVD) and mortality amongst others ([@bib2], [@bib3], [@bib4]). Weight loss (by lifestyle intervention or bariatric surgery) remains the only specific treatment for PCOS. The remaining treatments are mainly symptomatic (oral contraceptives for irregular periods, anti-androgens for hirsutism, ovulation induction for infertility) ([@bib5]). Hence, there is a need for better understanding of the pathogenesis of PCOS-related metabolic risk and comorbidities in order to develop effective therapies ([@bib6]).

Obstructive sleep apnoea (OSA) is common, affecting 17--26% of men and 9--28% of women; the prevalence being lower in women of reproductive age compared to men ([@bib7]). OSA is characterized by instability in the upper airways during sleep, leading to recurrent upper airway obstructions, sleep architecture disruption and cyclical changes in heart rate, blood pressure, sympathetic activity, intrathoracic pressure and oxygen saturations ([@bib7], [@bib8]). Obesity is very common in patients with OSA and PCOS ([@bib9]). In addition, OSA is associated with similar comorbidities to PCOS, such as IR, GDM, T2D, hypertension, impaired QOL, CVD and mortality ([@bib7], [@bib10]). Hence, it is plausible that OSA and PCOS might co-exist and that either condition could contribute to the comorbidities of the other ([@bib9]). This is further supported by a recent systematic review that showed that OSA prevalence in women with PCOS was 32% (95% CI: 13--55%) ([@bib11]). However, these studies were of small size (*n* \< 60), at risk of selection bias and cross-sectional design, barring the determination of the direction of relationship. Additionally, the study populations exclusively comprised patients with grade II obesity or higher. Hence, there is a need to examine the relationship between OSA and PCOS in a longitudinal population-based study, which allows to assess the impact of obesity.

Several mechanisms, other than obesity and insulin resistance, might increase the likelihood of OSA in women with PCOS compared to women without PCOS of similar adiposity including hyperandrogenism, low progesterone (due to anovulation) and increased oxidative stress ([@bib9]).

We hypothesized that women with PCOS are at increased risk of developing OSA compared to women without PCOS regardless of the degree of obesity. The primary aim of this study was to assess the risk of incident OSA in women with PCOS vs women without PCOS and examine the role of obesity in the observed relationships. A secondary aim was to assess predictors of incident OSA in women with PCOS.

Subjects and methods
====================

For full description of the methods please refer to the online supplement.

Ethics statement
----------------

The use of THIN data for research was approved by the South-East Multicenter Research Ethics Committee in 2003 without the need for informed consent. As per requirement of the ethical approval, further registration and authorization for this project were obtained from the relevant Scientific Review Committee (17THIN026).

Study design and setting
------------------------

We conducted a matched-controlled retrospective cohort study using data from UK general practices contributing to The Health Improvement Network (THIN) electronic database, as we have in previous studies ([@bib2], [@bib12], [@bib13]).

Study population
----------------

The open cohort extended from the 1st January 2000 (study start date) to the 15th May 2017 (study end date).

*Inclusion criteria*: All women who were aged 18--50 years at the index date (study entry) and had a documentation of PCOS at any time during the study period were included in the exposed group. Patients with any documentation of OSA prior to the index date were excluded. Women without documented PCOS at any time during the study period were included in the unexposed (control) arm. The index date was defined as the date of first documentation of PCOS for newly diagnosed cases and from the date patient became eligible if the first documentation of PCOS was prior to the eligibility date (for existing cases) (Supplementary Fig. E1, see section on [supplementary data](#supp1){ref-type="supplementary-material"} given at the end of this article).

Each exposed patient was randomly matched to two unexposed patients (1:2 ratio) for general practice, age at index date and BMI ([@bib14], [@bib15]).

To minimize the immortal time bias, each randomly matched eligible unexposed patient was assigned the same index date as their corresponding exposed patient ([@bib16]). Follow-up end date (exit date) was determined from the earliest occurrence of the first documentation of OSA, transfer to another practice, death or study end.

Selection of Read Codes and PCOS definition
-------------------------------------------

Read Codes to define PCOS, OSA and covariates were compiled using a methodical Read Code search strategy (see Supplementary Panel E1 and Table E1) Since there is a possibility of misclassification between PCOS and polycystic ovaries (PCO) due to the resemblance of codes during data entry, they have been combined in prevalence studies using general practice electronic databases ([@bib17]).

Statistical analysis
--------------------

Potential confounders and covariates were chosen based on biological plausibility and links to the exposure and outcome of interest (PCOS and OSA respectively). These included age, Townsend social deprivation index ([@bib14]), BMI, smoking status, diabetes mellitus, impaired glucose regulation ([@bib18]), hypertension ([@bib19]), hypothyroidism, antiandrogen medication and metformin. The critical value for statistical significance was set at 5% and 95% confidence intervals were used in the population estimate of hazard ratios. Further analysis included calculating the number and percentage of incident cases, person years and incidence rates. Unadjusted and adjusted hazard ratios were estimated using Cox regression models.

Sensitivity analysis was carried out to assess selection bias due to case definition (PCOS and PCO vs PCOS only) and survival bias due to inclusion of prevalent cases (who had the documentation of PCOS prior to becoming eligible for the study) ([@bib20]). In the primary analysis, we did not consider ethnicity as a covariate due to high missing values (48.9%). In a sensitivity analysis we assigned a separate ethnicity category for missing values and included into the Cox model as an additional covariate.

Another model confined to PCOS cases (excluding controls) was used to assess the association of PCOS with OSA while considering PCOS phenotypes and antiandrogen medication as covariates. STATA MP version 14.2 was used for data cleaning and analysis ([@bib21]).

Results
=======

Study population characteristics
--------------------------------

The study population included 76 978 women with PCOS and 143 077 matched control women from 763 general practices registered with THIN ([Fig. 1](#fig1){ref-type="fig"}). The median follow-up was 3.5 years (IQR: 1.38 to 7.14) with no significant difference between women with and without PCOS ([Fig. 1](#fig1){ref-type="fig"}). There was no obvious difference between women with and without PCOS with regards to age (median 30 years, IQR: 25--35), Townsend index for social deprivation, BMI and smoking status ([Table 1](#tbl1){ref-type="table"}). When compared to controls, women with PCOS were more likely to have T2D (2.2 vs 1.0%), hypertension (3.0 vs 2.0%), hypothyroidism (3.9 vs 2.3%) and impaired glucose regulation (0.6% vs 0.3%) ([Table 1](#tbl1){ref-type="table"}). The PCOS group was also more likely to develop diabetes mellitus during the follow-up when compared to control group (5.6 vs 2.6%).Figure 1Selection of patients with polycystic ovary syndrome (PCOS) and controls. A total of 14 417 129 patients were registered with 763 eligible practices during 2000 to 2017. Of these, 2 803 607 women were of 18 to 50 years old and were eligible. According to the criteria indicated in 'methods' section, there were 76 978 women with PCOS in PCOS cohort. The control cohort had 143 077 women who were matched within same general practice for age and BMI at a ratio of 1:2. There were 298 and 222 incident cases of sleep apnoea in PCOS and control cohorts respectively. Table 1Baseline characteristics of women with PCOS and control women without PCOS.CharacteristicsWith PCOS (*n* = 76 978)Without PCOS (*n* = 143 077)Age (years; mean ([s.d.]{.smallcaps}))30.2 (7.4)30.4 (7.3)Townsend score^\*^ 113 865 (18.0%)25 951 (18.1%) 212 716 (16.5%)23 910 (16.7%) 315 072 (19.6%)28 172 (19.7%) 414 498 (18.8%)27 341 (19.1%) 510 223 (13.3%)19 675 (13.8%)Missing data10 604 (13.8%)18 028 (12.6%)BMI (kg/m^2^; mean ([s.d.]{.smallcaps})28.6 (7.6)27.4 (6.4)BMI categorized \<25 kg/m^2^25 739 (33.4%)52 666 (36.8%) 25--29.99 kg/m^2^15 065 (19.6%)29 682 (20.8%) ≥30 kg/m^2^24 139 (31.4%)37 585 (26.3%) Missing or implausible data12 035 (15.6%)23 144 (16.2%)Smoking status Non-smokers56 105 (72.9%)101 370 (70.8%) Smokers17 383 (22.6%)32 778 (22.9%) Missing or implausible data3490 (4.5%)8929 (6.2%)Medical conditions at baseline Diabetes1694 (2.2%)1449 (1.0%) Hypertension2325 (3.0%)2805 (2.0%) Hypothyroidism2987 (3.9%)3228 (2.3%) Impaired glucose regulation†446 (0.6%)368 (0.3%)Ethnicity Caucasian-European36 670 (47.6%)58 182 (40.7%) Black-Afro-Caribbean1692 (2.2%)3222 (2.3%) South Asians3929 (5.1%)4266 (3.0%) Others including Chinese, Middle-Eastern1013 (1.3%)1781 (1.2%) Mixed-race715 (0.9%)1008 (0.7%) Missing (no codes found in Medical or AHD file)32 959 (42.8%)74 618 (52.2%)[^1]

The clinical features of PCOS and medications used in the study cohort are summarized in [Table 2](#tbl2){ref-type="table"}. Of the 76 978 women with PCOS, 22 307 (29.0%) were defined using PCOS Read Code while the remainder were defined using PCO Read Code (see Supplementary Table E1). Table 2PCOS diagnostic features and use of medication. Data are presented as *n* (%)CharacteristicsWith PCOS (*n* = 76 978)Without PCOS (*n* = 143 077)PCOS features at baseline Anovulation20 106 (26.1)10 463 (7.3) Any clinical androgen excess feature21 974 (28.6)23 231 (16.3)  Acne14 589 (19.0)19 371 (13.5)  Alopecia2749 (3.6)3820 (2.7)  Hirsutism7748 (10.1)1269 (0.9) Polycystic ovaries58 099 (75.5)0 (0)Medications Oral Contraceptive Pill (OCP) including an anti-androgenic progestin component\*22 798 (29.6)17 005 (11.9) Cyproterone17 346 (22.5)9381 (6.6) Drospirenone9685 (12.6)10 280 (7.2) Other antiandrogen192 (0.2)14 (0.0) Metformin18 571 (24.1)2925 (2.0)[^2]

Primary analysis
----------------

There were 298 incident cases of OSA among 76 978 women with PCOS and 222 among 143 077 women without PCOS. Incidence of OSA was significantly higher in women with PCOS vs the matched controls (8.1 vs 3.3 per 10 000 person-years of follow-up, *P* \< 0.0001) ([Table 3](#tbl3){ref-type="table"}). Women with PCOS had an increased hazard of developing OSA when compared to their matched controls (HR = 2.46, 95% CI: 2.07--2.93, *P* \< 0.001). Women with PCOS remained at increased risk of developing OSA compared to women without PCOS following adjustment for age, Townsend score, BMI, hypothyroidism at baseline, baseline and incident diabetes/IGR (adjusted HR = 2.26, 95% CI: 1.89 to 2.69, *P* \< 0.001) ([Table 3](#tbl3){ref-type="table"}). Table 3Risk of women with PCOS developing OSA compared to women without PCOS.Primary analysisSensitivity analysis (incident cases)Sensitivity analysis (PCOS specific Read Codes only)ExposedUnexposedExposedUnexposedExposedUnexposedTotal number of patients76 978143 07723 34943 10624 60344 991Incident OSA *n* (%)298 (0.39)222 (0.16)86 (0.37)60 (0.14)115 (0.47)63 (0.14)Person years368 203680 011112 290193 646107 959187 801Incidence rates per 10 000 person years8.13.37.73.110.73.4Hazard ratio (95% CI)2.46 (2.07--2.93)2.44 (1.76--3.40)3.11 (2.29--4.23) *P*-value\<0.001\<0.001\<0.001Adjusted hazard ratio (95% CI)\*2.26 (1.89--2.69)2.20 (1.58--3.06)2.93 (2.15--3.99) *P*-value\<0.001\<0.001\<0.001Adjusted hazard ratio (95% CI)^†^2.23 (1.87--2.66)2.14 (1.53--2.99)2.87 (2.10--3.92) *P*-value\<0.001\<0.001\<0.001[^3]

In addition to PCOS, we identified older age, increasing BMI and the presence of hypothyroidism at baseline as independent predictors of incident OSA (see Supplementary Table E2).

Sensitivity analysis
--------------------

Limiting the analysis to incident cases of PCOS (adjusted HR = 2.20, 95% CI: 1.58--3.06, *P* \< 0.001) or PCOS Read Codes only (adjusted HR = 2.93, 95% CI: 2.15--3.99, *P* \< 0.001) resulted in similar point estimates to those found in the analysis of the whole study population ([Table 3](#tbl3){ref-type="table"}). Adding ethnicity as an additional covariate did not alter our findings (adjusted HR 2.21, 95% CI: 1.85--2.64, *P* \< 0.001).

Analysis to assess if risk of OSA among women with PCOS is independent of BMI
-----------------------------------------------------------------------------

Increasing BMI was associated with increasing OSA incidence in women with and without PCOS, but the HRs were greater in women with PCOS vs control in all BMI categories (see [Fig. 2](#fig2){ref-type="fig"} and Supplementary Table E2). When compared to women without PCOS, women with PCOS showed a higher risk (adjusted HR (95% CI)) of developing OSA in all three BMI (kg/m^2^) categories (BMI \<25: 1.91 (0.92--3.97), *P* = 0.081; BMI 25--29.99: 2.25 (1.33--3.81), *P* = 0.003; BMI ≥30: 2.10 (1.72--2.56), *P* \< 0.001) (see [Fig. 2](#fig2){ref-type="fig"} and Supplementary Table E3).Figure 2Impact of BMI on the hazard of obstructive sleep apnoea (OSA). Women in both PCOS and control cohorts were subcategorized into lean, overweight and obese groups. The hazard of developing OSA among PCOS cohort in comparison to control cohort was assessed for each BMI sub groups.

Analysis to assess the role of factors other than BMI in OSA among PCOS women
-----------------------------------------------------------------------------

In addition to older age, increasing BMI and presence of hypothyroidism, we identified anovulation (adjusted HR (95% CI) 1.33 (1.05--1.69), *P* = 0.02), hirsutism (1.37 (1.05--1.80), *P* = 0.02) and treatment with metformin (1.69, 1.28--2.22, *P* \< 0.001) as predictors of incident OSA ([Table 4](#tbl4){ref-type="table"}). Table 4Predictors of OSA in women with PCOS (*n* = 76 978).CovariatesHazard ratio95% confidence interval*P* valueAge1.06(1.04--1.07)**\<0.001**Townsend 11.00(Reference level) 21.26(0.83--1.89)0.27 31.41(0.95--2.08)0.08 41.58(1.07--2.33)**0.02** 51.67(1.10--2.53**)0.02**Missing1.23(0.77--1.97)0.38BMI category \<25 kg/m^2^1.00(Reference level) 25--29.99 kg/m^2^3.01(1.60--5.69)**0.001** ≥30 kg/m^2^12.50(7.24--21.58)**\<0.001** Missing3.64(1.91--6.95**)\<0.001**Diabetes or IGR\*0.72(0.44--1.18)0.19Hypothyroidism1.76(1.20--2.58)**0.004**Anovulation1.33(1.05--1.69)**0.02** Androgen excess features  Hirsutism1.37(1.05--1.80)**0.02**  Acne0.85(0.61--1.19)0.35  Alopecia0.97(0.64--1.46)0.89 Metformin1.69(1.28--2.22)**\<0.001**  Antiandrogen drug0.77(0.57--1.05)0.10[^4]

Discussion
==========

This is the first large longitudinal study assessing the temporal relationship between PCOS and OSA in a European population and that accounted for the role of obesity and adjusted for a large number of potential confounders. We found that women with PCOS were at increased risk of developing OSA compared women without PCOS regardless of the severity of obesity and independent of a wide range of potential confounders. We also found that hirsutism and chronic anovulation, clinical features of androgen excess, which is closely linked to insulin resistance in the context of PCOS, were independent predictors of OSA development in women with PCOS.

A recent study from Taiwan also found an increase OSA incidence in women with PCOS, but was of much smaller sample size (*n* = 9190 vs 220 055) and did not match for BMI; in addition, the adjustment for confounders was limited and did not explore the possible underlying mechanisms ([@bib22]).

The prevalence of OSA in women with PCOS has been investigated in several small-scale cross-sectional studies ([@bib9]). Two recent meta-analyses showed an estimated OSA prevalence (based on polysomnography or portable level II devices) of 36.1% (95% CI: 22.4--51.0%) and 32% (95% CI: 13--55%) in women with PCOS ([@bib23], [@bib24]). However, the prevalence of OSA in women with PCOS varied widely from 0 to 69% ([@bib9]). This big variation in OSA prevalence between studies is attributed to multiple factors, including the application of different AHI cut-offs to diagnose OSA, small sample sizes, variation in obesity prevalence and potential selection bias due to recruitment from specialized clinics, raising the possibility that the results many not be generalizable ([@bib9]). Our current study addresses many of these gaps by conducting a population-based longitudinal study of a large sample size that included patients with normal, overweight and obese BMI categories. The impact of PCOS on risk of OSA was stronger in overweight than in obese women; however, this needs to be interpreted with caution given the confidence intervals of effect sizes overlap.

The cross-sectional studies that showed low prevalence rates of OSA in women with PCOS were mainly carried out in leaner cohorts, hence suggesting that the high prevalence of OSA in women with PCOS was only applicable to women with obesity. Whether women with PCOS were truly at increased risk of OSA compared to women with similar obesity but without PCOS was unclear ([@bib9], [@bib23], [@bib24]). Our study addressed this limitation of earlier studies by including a control group of women matched for BMI amongst other important covariates, and our results show clearly that women with PCOS were at increased risk OSA compared to women without PCOS. In addition, we have shown that this increased risk of OSA in women with PCOS was evident irrespective of whether patients were normal weight, overweight or have obesity. However, the observed relationships were stronger in women who were overweight or had obesity.

Several mechanisms might explain the link between PCOS and OSA and explain the findings of this study ([@bib9], [@bib25]). Androgen excess is a cardinal feature of PCOS and androgens are implicated in the pathogenesis of OSA as they affect upper airway stability and ventilatory drive ([@bib9]). OSA is consistently more common in men than women ([@bib26], [@bib27]), which may also point to androgens as a contributing factor. Our data support this notion as a documented diagnosis of hirsutism, a clinical manifestation of androgen excess, was an independent predictor of incident OSA. In addition to androgen excess, oxidative stress and low progesterone might play a role in the observed relationship between PCOS and OSA ([@bib25]). Oxidative stress can contribute to the pathogenesis of OSA by causing dysfunction in the carotid body chemoreceptors resulting in ventilatory instability ([@bib28]). Progesterone is a respiratory stimulant and can result in lowering upper respiratory resistance ([@bib29]). Furthermore, OSA is associated with lower progesterone in women ([@bib30]) and low progesterone affects the ventilatory drive ([@bib9], [@bib31], [@bib32]). Our results also support this potential mechanism as anovulation predicted incident OSA. Insulin resistance, a feature of OSA and a predictor of incident apnoea can also contribute to the observed relationships in this study ([@bib33], [@bib34]).

OSA is associated with multiple comorbidities including road traffic accidents, hypertension, T2D, CVD, and mortality, which are similar to PCOS comorbidities (except the road traffic accidents). However, whether OSA increases the risk of these comorbidities in women with PCOS is largely unknown. A recent systematic review and meta-analysis showed that women with both PCOS and OSA are more likely to have hirsutism, hypertension, insulin resistance, hyperlipidaemia, and dysglycaemia than women with PCOS only ([@bib24]). However, these findings were based on small-scale cross-sectional studies with a high risk of bias ([@bib9]). Hence, longitudinal and interventional studies to assess the temporal relationship and causation are needed.

The findings of our study need to be interpreted within the context of the limitations. We carried out an observational cohort study using data from primary care and hence we did not have access to the results of the polysomnography, polygraphy or oximetry such as the AHI, oxygen desaturation index and other hypoxemic measures. In addition, since we and other studies ([@bib14], [@bib17]) have observed a much lower prevalence of PCOS and OSA in electronic medical records, it is possible that many patients with PCOS and OSA remained undiagnosed. This may be due lack of diagnosis or incomplete recording of PCOS and OSA diagnosis in primary care setting. It is possible that patients with PCOS who come to the attention of the treating clinician represented the more severe phenotype which may have resulted in an overestimate of the effect size. This may limit the generalizability of our findings to patients with milder form of disease. On the other hand, the unexposed population may have patients with undiagnosed PCOS which could potentially lead to an underestimation of the effect size.

Nevertheless, our study has several strengths including the large sample size, the longitudinal nature of the study, the matched controlled design and the adjustment for a wide range of confounders including BMI. In addition, this was a population-based study rather than data from tertiary centres and hence the findings are much more generalizable. The longitudinal design of the study also allowed us to assess the predictors of OSA in women with PCOS.

We conclude that women with PCOS are at increased risk of developing OSA compared to women without PCOS independent of obesity and other potential cofounders. This increased risk was present in patients with normal weight, overweight and obesity. Clinicians treating women with PCOS should have a low threshold to test for OSA. In addition, our findings suggest that clinical features of hyperandrogenism and low progesterone may contribute to the increased risk of OSA in women with PCOS. Whether OSA worsens the long-term sequelae of PCOS and whether CPAP treatment has favourable impacts on women with PCOS and OSA remains to be examined.
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[^1]: \*Townsend score -- presented as quintiles with 1 least deprived and 5 most deprived. ^†^(Includes impaired fasting glucose and impaired glucose tolerance).

[^2]: \*Use of either cyproterone acetate or drospirenone. Since some patients were prescribed both cyproterone and drospirenone during the period covered, the number of OCP users is slightly smaller than the arithmetic sum of the numbers of cyproterone and drospirenone users.

[^3]: \*Adjusted for age, Townsend score, BMI, diabetes or impaired glucose regulation at baseline and hypothyroidism at baseline. ^†^Adjusted for age, Townsend score, BMI, diabetes or impaired glucose regulation up to end of follow-up and hypothyroidism at baseline.

[^4]: \*Impaired glucose response (includes impaired fasting glucose and impaired glucose tolerance). Values in boldface indicate statistical significance.
